Financial reports
10-Q
2024 Q1
Quarterly report
10 May 24
ARS
2023 FY
Annual report to shareholders
20 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
21 Mar 23
10-K
2022 FY
Annual report
7 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
Current reports
8-K
Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
9 May 24
8-K
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
9 May 24
8-K
Submission of Matters to a Vote of Security Holders
30 Apr 24
8-K
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
29 Feb 24
8-K
Departure of Directors or Certain Officers
2 Feb 24
8-K
Strengthens financial flexibility to support the Company’s continued growth
2 Jan 24
8-K
Changes in Registrant's Certifying Accountant
18 Dec 23
8-K
Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2 Nov 23
8-K
Other Events
11 Sep 23
8-K
Entry into a Material Definitive Agreement
1 Sep 23
Registration and prospectus
S-8
Registration of securities for employees
10 May 24
S-8
Registration of securities for employees
9 May 23
F-6EF
Automatic registration for ADRs (foreign)
7 Mar 23
S-3ASR
Automatic shelf registration
7 Mar 23
S-8
Registration of securities for employees
15 Nov 22
424B5
Prospectus supplement for primary offering
11 Aug 22
424B5
Prospectus supplement for primary offering
9 Aug 22
S-3
Shelf registration
19 Mar 21
POS AM
Prospectus update (post-effective amendment)
19 Mar 21
424B3
Prospectus supplement
4 Jan 21
Proxies
Other
EFFECT
Notice of effectiveness
30 Mar 21
EFFECT
Notice of effectiveness
26 Mar 21
CORRESP
Correspondence with SEC
26 Mar 21
UPLOAD
Letter from SEC
25 Mar 21
EFFECT
Notice of effectiveness
28 Aug 20
CORRESP
Correspondence with SEC
25 Aug 20
UPLOAD
Letter from SEC
24 Aug 20
EFFECT
Notice of effectiveness
1 Jun 18
CORRESP
Correspondence with SEC
30 May 18
UPLOAD
Letter from SEC
29 May 18